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ABSTRACT 
 
Besides the classical evolutionary model of colorectal cancer (CRC) defined by 
the stepwise accumulation of mutations in which normal epithelium transforms through 
an intermediary polyp stage to cancer, few studies have proposed alternative modes of 
evolution (MOE): early eruptive subclonal expansion, branching of the subclones in 
parallel evolution, and neutral evolution. However, frequencies of MOEs and their 
connection to mutational characteristics of cancer remain elusive. In this study, we 
analyzed patterns of somatic single nucleotide variations and DNA copy number 
aberrations (CNAs) in CRC with residual polyp of origin and in cancer free polyps from 
27 patients in order to determine this relationship. For each MOE we defined an expected 
pattern with characteristic features of allele frequency distributions for SNVs in cancers 
and their matching adenomas. From these distinct patterns, we then assigned an MOE to 
each CRC case and found that stepwise progression was the most common (70% of 
cases). We found that CRC with the same MOE may exhibit different mutational spectra, 
suggesting that different mutational mechanisms can result in the same MOE. Inversely, 
cancers with different MOEs can have the same mutational spectrum, suggesting that the 
same mutational mechanism can lead to different MOEs. The types of somatic 
substitutions, distribution of CNAs across genome, and mutated pathways did not 
correlate with MOEs. As this could be due to small sample size, these relations warrant 
further investigation. Our study paves the way to connect MOE with clinical and 
mutational characteristics not only in CRC but also to neoplastic transformation in other 
cancers.  
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INTRODUCTION 
Discussion of CRCs 
Colorectal cancer (CRC) is the third most common cancer type with respective 
incidence and mortality rates of 40.7 and 14.8 per 100,000 people [1]. CRC frequently 
metastasizes to the liver, intestinal lymph nodes, lung, and abdominal cavity [2]. Even 
though the recent extensive screening and thorough removal of any sighted polyps 
substantially decreased the incidence rate, studying the causes of the cancer development 
seems crucial in its prevention and development of appropriate treatments [3]. 
The foundation for the studies of genetic evolution in colorectal cancer (CRC) 
was built upon the finding first presented in the seminal work by Fearon and Vogelstein 
that the accumulation of genetic alterations led to neoplastic transformation in the colon 
to CRC [4]. This widely accepted and dominant paradigm that CRC arises in a linear 
model of accumulated genetic mutation and large-scale genomic disruptions of 
chromosomal instability continues to be the infrastructure upon which extensive research 
on carcinogenesis is based [5]. In this classical model of CRC, carcinogenesis is 
presumed to follow a linear trajectory from normal colon tissue to a precancerous lesion, 
known as an adenomatous polyp, to cancer. Although the large structural variations and 
copy number aberrations (CNA) along with the typical accumulation of point mutations 
suggested that the carcinogenesis of colorectal cancer required chromosomal instability 
(CIN), this speculation was debunked with the discovery of microsatellite Instability 
(MSI) type colorectal cancer [6]. According to Boland et al., microsatellite sequences are 
regions of simple repeats that are particularly prone to genetic mistakes due to this 
repeating characteristic. Naturally, MSI refers to the phenotype of a large number of 
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mutations within these microsatellite sequences. In his study, Boland states that this is 
either due to abnormal DNA repair systems, specifically, deficient DNA mismatch repair 
(MMR) or due to hyper-methylation in MLH1 gene MSI. The colorectal cancer 
development through MSI is different from the traditionally studied CIN types as the 
large number of mutations in microsatellite sequences is often accompanied by an 
absence of CNA. This lack of large structural variation is one of the potential reasons 
why MSI cases have a better prognosis than CIN cases [7]. 
In addition to the classification of CRC via developmental mechanisms, 
hereditary status also can classify colorectal cancer into two types: familial and sporadic. 
Approximately 30% of the CRC is hereditary, and among these, hereditary non-polyposis 
colorectal cancer (HNPCC) and familial adenomatous polyposis (FAP) are the two types 
that are extensively studied [8]. HNPCC, also known as the Lynch syndrome, is a rare 
genetic disorder with germline variants in DNA MMR [6]. Although it accounts for 
approximately 4% of all CRC cases, HNPCC can increase the risk of developing 
adenomas up to 80% [9,10]. Because of their defective DNA MMR, Lynch syndrome is 
often associated with a high level of microsatellite instability (MSI-H). Sporadic 
colorectal cancer, on the other hand, refers to non-hereditary colorectal cancer. As 
Boland explains in his study, these develop due to acquired somatic mutations during the 
lifetime of the individual and can also develop with microsatellite instability. In fact, it 
was found that approximately 12% of the colorectal cancers diagnosed have developed 
MSI through the accumulation of somatic mutations [6]. 
One of the most extensively studied pathways relevant to colorectal cancer would 
be the Wnt-signaling pathway. In a normal cell, Wnt extracellular protein binds to its 
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receptor and initiates a cascade leading to an accumulation of β-catenin proteins [11]. 
According to the authors, the Wnt-signaling pathway works as follows: β-catenins 
subsequently are transported into the nucleus, and the recruitment of these β-catenins 
promotes proliferation. When the Wnt proteins are not present outside the cell, their 
receptors are not active and cytoplasmic proteins would recruit any excess β-catenins and 
degrade them within the cell to prevent the translocation of the β-catenins and 
unnecessary proliferation that is followed. One of the cytoplasmic proteins responsible 
for maintaining β-catenin at low levels during a normal state is the Adenomatus Polyposis 
Coli (APC) gene [12]. In his study, Markowitz states that APC gene is a well-known 
tumor suppressor because mutations in this gene allow β-catenins to both increase in 
number and localize to the nucleus, resulting in an uncontrollable proliferation. 
Inactivation in the APC gene has been known to be one of the hallmarks of colorectal 
cancer progression, especially through a hereditary knock out of one of the alleles that 
predisposes individuals to a higher risk of developing CRC [13]. 
Another major mechanism that is well studied in colorectal cancer is the p53, a 
well-known tumor suppressor gene. The role of p53 inactivation in cancer progression 
has been observed across multiple cancer types [14,15]. While the normally functioning 
p53 acts as a checkpoint to various DNA damage by regulating cell cycle arrest, DNA 
repair, or apoptosis, inactivation of the gene promotes cells to grow insensitive to these 
regulating measures. In colorectal cancers, p53 was reported to be commonly inactivated 
through the entire short arm deletion of chromosome 17 [16]. 
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Sequencing Technology 
While cancer has been characterized clinically and histologically, with a focus on 
the major genes and specific pathways that contribute to the development of cancer, the 
revolution in cancer studies came with the advent of sequencing technology. Methods of 
sequencing DNA strands have existed since the 1970s with the goal of obtaining a 
complete sequence of small nucleotide fragments [17]. Sanger sequencing was really the 
first method to produce and sequence small fragments of DNA strands. As with any 
sequencing technology, Sanger sequencing can be divided into two different types: de 
novo sequencing and re-sequencing with a reference sequence [18]. As explained by 
Shendure, de novo sequencing is based on the shotgun method of cutting DNA into 
random segmentations and transformation of the segments by bacteria for cloning. Once 
the bacterial colony is grown, the plasmids are isolated and sequenced with ddNTPs that 
terminate the addition of new nucleotides in a growing strand. The resulting strands were 
run on the electrophoresis for sequence determination. Re-sequencing was simply 
performing the polymerase chain reaction (PCR) since the restoration of the original 
sequence from the segments can be done if it is already known where the segments are 
supposed to be ligated. After cycles of denaturation of DNA in high temperatures 
followed by annealing of it in low temperatures and elongation, PCR generates multiple 
DNA strands accurately. These DNA strands of varying length can be then separated by 
weight via electrophoresis and the different lanes would indicate the appropriate 
nucleotide letters in a sequential manner. 
Despite the ability of Sanger sequencing to obtain the sequence of DNA strands, 
nation-wide efforts in obtaining a complete sequence and mapping of our entire genome 
	5	
through initiatives such as the Human Genome Project was limited by the scalability of 
production and sequencing of DNA strands needed for the projects. This need for a mass 
production in DNA sequencing led to the introduction of second-generation sequencing, 
more commonly known as next-generation sequencing. As opposed to the traditional 
sequencing of DNA strands floating in aqueous solutions, second-generation sequencing 
was founded in an array-based technology in which the DNA fragments were cloned in 
parallel for faster results [19]. With this new array-based technology, hundreds of 
millions of sequencing reads could be processed simultaneously. This significantly 
increased the efficiency of sequencing but required an image capture that was prone to 
error in calling the nucleotide bases, especially in the regions of repeated nucleotide 
sequence [20]. Thus, this advancement came at the cost of shorter read-lengths and 
decreased accuracy compared to Sanger sequencing. Consequently, the computationally 
intensive optimization efforts following the introduction of sequencing technology led to 
increases in its accuracy along with a decrease in price [21]. This resulted in a drastic 
transformation of the field of genomics and other areas of biology with new applications 
of sequencing technology still being devised today [22,23]. 
This technological advancement in the analysis of the genome at a large scale led 
to its application on cancer via two major projects, one beginning in 2001 and another in 
2005 [24] (see https://cancergenome.nih.gov/abouttcga/ overview/history). The first 
project, called the Cancer Genome Project, was based in Wellcome Trust Sanger 
Institute. The project focused on the cataloging of recurrently detected somatic mutations 
that are found by comparing the tumor tissue of a patient to a normal tissue in the same 
person. Researchers studying the mutations were able to differentiate them into the 
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“driver” mutations, which impair specific genes to propel the development of tumor, and 
the “passenger” mutations that occur randomly with inconsequential effect on the tumor 
growth. These efforts resulted in a large online database of somatic mutations in cancer 
called Catalogue Of Somatic Mutations In Cancer (COSMIC) [25]. The other major 
project in sequencing cancer tissues was the Cancer Genome Atlas (TCGA) project in 
2005. The purpose of this project was to better understand the genetic mechanisms 
involved in cancer so that it can be better diagnosed and treated (see 
https://www.genome.gov/10000905/national-advisory-council-for-human-genome-
research/). Unlike the study of normal tissues, cancer analysis using the sequencing 
technology can involve further complications. For instance, when a bulk tissue of a tumor 
is excised, tumor microenvironment within the tissue often also includes non-cancerous 
cells [26]. Aran illustrates how this decrease in the tumor purity can have significant 
effects on the analysis of cancer. In addition to the tumor purity, regional sequencing 
studies have shown that genetic intratumoral heterogeneity makes it difficult to capture 
all of the genomic landscape of a cancer tissue [27]. Despite these limitations, the 
sequencing technologies truly revolutionized the field of cancer genomics. 
In order to understand how genomic information is obtained from the sequencing 
data, several terms need to be defined. Coverage in sequencing refers to the number of 
times the genomic region is “covered” or sequenced, assuming a constant length of reads 
mapping in a random distribution [28]. Once coverage of the sequence is determined, 
allele frequency (AF) of a single nucleotide variant (SNV) can be calculated. This allele 
frequency, or allele ratio, of a SNV can be calculated by dividing the number of reads 
supporting the reference nucleotide letter by the number of reads supporting the other 
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nucleotide letter at that particular position [29]. There are several bioinformatics tools 
that both identify all SNVs and calculate the AF for them. These often filter out the reads 
that are uncertain in their calls or mapping before identifying all SNVs and use a 
statistical model to classify the SNVs [30]. Copy number variations (CNVs) are defined 
as genomic regions with a copy number ratio that deviates away from the normal ratio of 
2 and are generally identified by comparing the relative copy number ratio calculated 
from the read coverage across the genome [31]. 
The ability to analyze multiple samples using the sequencing technology at a 
relatively cheap price opened up new opportunities for various cancer genome-wide 
association studies. Comparing cancer cases at such a large-scale highlighted specific 
genes most frequently mutated in particular subtypes of cancer, which subsequently 
provided clinical benefits such as the identification of specific targets for different cancer 
types. According to one TCGA study on colorectal cancer, eight most commonly mutated 
genes in non-hypermutated CRC cases were APC, TP53, KRAS, PIK3CA, FBXW7, 
SMAD4, TCF7L2, and NRAS, while the most commonly mutated genes in hypermutated 
CRC cases were identified as ACVR2A, APC, TGFBR2, MSH3, MSH6, SLC9A9 and 
TCF7L2 [32]. 
In addition to determining genes with the most recurrent mutations, identifying 
somatic mutations using sequencing technology allowed for the analysis of the specific 
mutational mechanisms. In 2013, as part of the Cancer Genome Project, researchers 
classified each substitution mutation found in a cancer sample into one of the 96 possible 
tri-nucleotide sequences organized by six different base substitution classes and 
examined the relative distribution [33]. The researchers showed that by applying this 
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holistic view of the landscape of the somatic mutations in each cancer sample across 
many cancer types, they observed and validated distinct patterns or signatures. Many of 
these signatures were assigned specific functions or characteristics that were most 
probable based on the association study. This analysis offers a new way to better 
understand the mutational mechanisms from somatic substitution mutations. 
Modes of Evolution and Sequencing of CRC 
Since the introduction of next generation sequencing technology, improved ability 
to accurately characterize cancer genomes allowed researchers to explore and challenge 
the idea of sequential progression in carcinogenesis of CRC and this effort resulted in 
three additional evolutionary models to address carcinogenesis. One recent study on the 
distribution of somatic mutations in CRC proposed an extension of the linear model into 
a quick eruptive accumulation of mutations in the polyp followed by subclonal 
competition and a plateau of extensive mutation accumulation in the resulting cancer 
[34]. This phenomenon results from a lack of selection pressure in combination with high 
rate of mutation accumulation. One noteworthy aspect of this model, also known as the 
‘Big Bang,’ is that it describes how early mutations shape the high intratumoral 
heterogeneity (ITH) observed in the late stage of CRC and may be associated with a more 
aggressive clinical behavior and decreased rates of survival [27]. 
Another study postulated a parallel evolution involving a separate lineage of 
private, cancer- and adenoma-specific mutations branching out from the early clonal 
mutations shared between the two tissues [35]. Due to this divergence, cancer exhibits a 
different mutational architecture than the traditionally expected expansion of the 
subclonal populations present in the polyp. In parallel evolution, driver mutations may be 
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present in subclones and multiple independent subclonal expansions may persist given 
that they may be of equal fitness. Thus one subclone does not confer a selective 
advantage over another subclone, which may in fact have the same driver mutation but 
unique private mutations. In some cases, the polyp accumulates a greater number of 
mutations than cancer, while in others the cancer accumulates more mutations than the 
polyp, suggesting that the number of mutations alone cannot determine whether a CRC 
will undergo parallel evolution. 
Lastly, the possibility of cancer evolution following a simple neutral power-law 
was explored based on the finding that some cancers exhibit several distinct distributions 
of the allele frequency of somatic mutations in their cancer lineage in which one evinces 
selection pressure while another does not. The notion is that the distribution of passenger 
mutations with low allele frequencies with respect to the clonal mutations near the allele 
frequency of 0.5 would follow a 1/f distribution [36]. On the other hand, a lineage 
exerting selection pressure would have driver mutations represented as an additional 
subclonal peak located between the peak of the passenger mutations and that of the clonal 
mutations [37]. 
These four Modes of Evolution (MOEs), stepwise, eruptive, parallel, and neutral, 
offer possible explanations for the temporal relationship among the different types of 
genome wide alterations as well as intra- and inter-tumoral heterogeneity. The 
importance of knowing the features of MOEs with the highest impact on the polyp or 
tumor’s behavior is highlighted by the genetic evolution in glioblastoma multiforme 
(GBM). In one study, the degree of persistent mutations from the primary tumor that 
were also present in the recurrent tumor differed based on the MOE of the primary tumor 
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[38]. The authors found that the recurrent tumors carried 75% of the mutations present in 
the primary tumor with linear MOE compared to those with parallel MOE in which 
recurrent tumors shared only 25% of the mutations in the primary tumor. The recurrence 
of the cancer, which rarely can be successfully treated and cured, was genetically 
represented by those early mutations present in the primary tumor that had developed 
resistance to chemotherapy. If it were possible to recognize all functionally relevant 
mutations in the primary tumor, and develop treatments for each of these mutations, 
conceivably it would be possible to prevent recurrences. Thus, studying the MOEs and 
understanding the characteristics of clinical cases in relation to the evolutionary path that 
led to malignant transformation may be leveraged to improve accurate prognostication 
and provide targets for personalized treatment options. 
We previously reported that at least 10% of CRC have the contiguous residual 
polyp of origin (CRC RPO+) identifiable in the surgically resected specimen [39]. We 
performed whole genome sequencing and analysis of such CRC RPO+ cases, which 
included matched peripheral blood leukocytes, normal colon a minimum of 8 cm distant 
from the polyp and/or cancer edge, the cancer adjacent polyp (CAP) and the contiguous 
CRC (Fig. 1). Comparative analysis between CRC RPO+ and CRC without residual 
polyp of origin (RPO-) revealed essentially the same histology, gene expression patterns, 
mutated genes/pathways, as well as the same stage-adjusted disease free and overall 
survival. Similarly, the CAP component is highly likely to represent the intermediary 
state between normal colon epithelium and CRC RPO+ because it is in direct contiguity 
with the cancer. This strongly argues that CRC RPO+ is a valid model to study neoplastic 
transformation in the colon [39]. 
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In this study, we analyzed patterns of somatic mutations in the CRC RPO+ cases 
to determine the relationship between different MOEs in the transformation from normal 
colon cells to CRC and mutational characteristics of CRCs, cancer adjacent polyps, and 
cancer free polyps. To determine this relationship, we analyzed the same whole genome 
sequence data from our previous study [39]. The cases included corresponding distant 
normal colon epithelium, CAP and the cancer from 13 CRC RPO+ cases and 14 CFP 
cases with matching distant normal or PBL for each case, which make up more than 80 
tissue samples extracted from 27 patients. Cases without the matched normal colon 
epithelial tissue were excluded. 11 of these cases were clinically determined to be 
aggressive, having either recurred or presented as advanced stage IV disease. 
 
Figure 1: Depiction of the regions of biopsy 
CRC with residual polyp of origin (top red box) refers to cancer that has a polyp located 
physically adjacent to the cancer (bottom black box). Matching normal colon tissue was 
also harvested at a distance > 8cm from the cancer. 
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MATERIALS AND METHODS 
Patient sample characteristics 
All tissues were collected from patients consented to the IRB approved Biobank 
for Gastrointestinal Health Research [BGHR] (IRB 622-00, PI LA Boardman) at Mayo 
Clinic between 2000-2016. 1 cm2 portions of surgically or endoscopically resected 
cancers from patients with CRC RPO+ were snap frozen in liquid nitrogen and 
maintained long term at -80 °C. Cancer adjacent polyps (CAPs) were identical to cancer 
free polyps (CFPs) in size (1 to 2cm, 2-5 cm and >5cm) and histology (tubular or villous 
subtype), and the degree of dysplasia (low-grade). Matched normal colonic epithelium 
were collected at least 8cm away from the polyp/tumor margin. This study did not 
include subjects with family history of FAP or Lynch syndrome and any other hereditary 
CRC or inflammatory bowel disease. 
Tissue preparation and Whole Genome Sequencing 
An Hematoxylin and Eosin slide circled by a pathologist to enrich for distant 
normal colon epithelium a minimum of 8 cm away from the polyp or tumor edge, polyp 
and cancer tissues was used a guide slide for macrodissection of these three tissue 
compartments. DNA from peripheral blood leukocytes (PBL) from the patients was 
obtained on a subset of these patients. DNA was extracted using the PureGene method 
and was quantified with appropriate kits on the Qubit Fluorometer. Samples were 
sequenced at the Broad Institute on the Illumina HiSeq X instruments producing 150 base 
pair, paired-end reads to meet a goal of 30x mean coverage. All data from a particular 
sample was aggregated into a single BAM file using the Picard Tools 
(https://broadinstitute.github.io/picard/). 
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Mutation Frequency Detection 
Four different somatic variant callers were used to identify SNVs in the polyp and 
cancer against the matched normal tissue or PBL with default options: MuTect, 
SomaticSniper, Strelka, and VarScan [30,40–42]. We only took SNVs detected by at least 
two callers. Variant allele frequencies for those SNVs were calculated from sample BAM 
files for each patient using an in-house script. For functional annotations of the variants, 
we used Variant Effect Predictor (http://www.ensembl.org/Tools/VEP). 
Mutational Motifs Calling 
From the list of SNVs called in cancer, somatic SNVs that were also called in 
polyp were subtracted from the list to ensure mutual exclusivity between the cancer and 
polyp SNVs. Cancer sample in the cases A04, A09, A11, A14, and A15 did not have 
enough somatic SNVs to exclude the SNVs found in polyp and thus all somatic mutations 
found in cancer were included. Each somatic SNV within a sample was categorized into 
the corresponding transversion or transition substitution mutation into one of the 96 tri-
nucleotide possibilities. After normalization, correlation coefficient was calculated based 
on these vectors of 96 integers for each sample and UPGMA-based hierarchical 
clustering was performed on the samples based on this coefficient. The intensity of the 
colors was adjusted within each of the six panels per sample for easier detection of the 
patterns. All the statistical analyses were performed using R software. Heatmaps were 
generated using the ggplot() function in the R package, ggplot2. Hierarchical clustering 
was performed with the hclust() function with default parameters. Correlations 
coefficients were calculated using the cor() function with the Pearson method. 
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Pathway from Related Genes 
For each of the CFP, CAP, and cancer, a list of genes with somatic mutations was 
submitted to the Database for Annotation, Visualization and Integrated Discovery 
(DAVID) for functional pathway analysis. To account for the background mutation rate, 
only the genes determined by the MutSig to be significantly mutated were used in the 
analysis (p-value <0.05). The number of significantly mutated genes for CFP, CAP, and 
cancer were determined to be 195, 123, and 137 respectively. The results of the multiple 
hypothesis tests were corrected using Benjamini method (FDR < 0.05). 
CNA Analysis 
The regions of deletion and duplication was genotyped using CNVnator using a 
bin size of 200bp and only the regions with a copy number of > 1.75 and < 2.25 in 
normal samples were considered. To further filter the CNAs, only the regions with copy 
number difference greater than 0.2 with respect to normal tissue were chosen. A pairwise 
similarity metric, M, is based on Jaccard similarity coefficient was defined as follows: 
! = !!"#,!"# +   !!"#,!"#!!!"# + !!!"# + !!!"# + !!!"# − ( !!"#,!"# +   !!"#,!"#)!"# !!!  
 
The similarity metric M is equal to the region, R, of duplications or deletions in 
both samples over all regions of duplication or deletion for each chromosome. Because 
these are scores per chromosome, calculating the summation of these scores represents a 
similarity score between a pair of samples across their entire genome with the exception 
of X and Y to ensure comparison across genders. For each tissue type, chromosomes with 
significantly recurrent aneuploidies compared to others were determined by a Wilcoxon 
signed-rank test. With a pairwise similarity metric across all the samples, UPGMA-based 
hierarchical clustering was performed. Heatmaps were generated by dividing the genomic 
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regions into segments of 50kb and using the ggplot() function in the R package, ggplot2. 
Hierarchical clustering was performed with the hclust() function with default parameters. 
RESULTS 
Utility of mutation AFs across neoplastic transformation for MOE classification 
We observed distinct patterns in the allele frequency distribution of each pair of 
cancer and matching polyp characterized by 1) two gaps in AF; 2) one gap in AF; or 3) 
no gap (Appendix Figure 1-14). We hypothesized that these patterns are representative 
of CRC evolution. Consequently, we derived an expected pattern of AF distributions in 
CRC and its corresponding polyp for each MOE based on its key characteristics. An 
illustration of the clonal lineages corresponding to each model is shown in Figure 2. For 
stepwise and eruptive MOEs, it is expected that most SNVs are shared between the 
adenoma and its corresponding cancer. Moreover, selective pressure is a common feature 
in stepwise MOE and can increase the AF of certain subclonal mutations nearly to the 
level of AF present in shared clonal mutations. For parallel MOE, where the adenoma 
and cancer branch early in their evolution to independent pathways, most SNVs are 
expected to accumulate after the branch point between a polyp and cancer. Thus, most of 
these SNVs are polyp or cancer specific, rather than shared. One important distinction 
between stepwise and parallel MOEs is that the parallel MOE has adenoma and cancer 
separately evolving along their respective subclonal lineage, implying distinct adenoma- 
and cancer-specific mutations conferring a growth advantage for each tissue 
compartment. Thus, the AF of private mutations in polyp compartment of parallel MOE 
cases would both be close to 0.5 (blue dots in Fig. 2), while this is not the case for 
stepwise MOE. A key feature of neutral MOE is the little to no selective pressure 
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represented by a lack of clear distinction between early-shared (gray cluster) and late-
shared mutations (the rest). CRC originating via an eruptive MOE is characterized by the 
development of all shared clonal mutations prior to the pre-cancer polyp phase followed 
by little to no selection so that the shared clonal mutations early in transformation would 
include clusters of early mutations (brown, green, and light blue cluster) in addition to the 
grey cluster of SNVs. 
The anticipated AF distribution for the union of somatic SNVs per patient (i.e., 
discovered both in adenoma and cancer) is a characteristic feature of MOE in both the 
adenoma and cancer compartments. Gradual transition from adenoma to cancer in 
stepwise MOE will result in a gap in the AF distribution in cancer and small or no gap in 
adenoma. However, no such gaps are expected in the distributions for neutral MOE, as 
SNVs with all AFs are shared between adenoma and cancer. Long independent evolution 
of adenoma and cancer in parallel MOE will results in clear gaps in the two distributions. 
Early shaping of the shared clonal mutations in eruptive MOE will results in a gap in AF 
distribution of adenoma, but at no or less pronounced gap in AF distribution of cancer. 
Purity of a tissue, i.e., fraction of malignant cells, is generally determined by a 
pathologist visually inspecting histological slides of the tissue and the purity level varies 
from sample to sample [26]. Lower purity level in adenoma sample would shift down the 
overall somatic SNV AF distribution in adenoma towards zero and could potentially 
decrease the gap observable in the 2D plot. However, while purity level can shift, shrink, 
or expand the AF distribution and affect the absolute AF, the relative pattern of the 
distribution as a whole remains the same. Thus, comparison of the relative AF between 
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the shared and the private mutations can be used to infer the existence of selective 
pressure in a CRC without the influence of the purity level difference across samples. 
 
Figure 2:	 Schematic representation of the four Modes of Evolution (MOEs) in the 
transformation from adenoma to colorectal cancer 
At the very top is the classical sequential stepwise progression. Next, the parallel model 
depicts the branching of the subclones. Neutral evolution has subclonal expansion in the 
absence of selective pressure. Lastly, the eruptive ‘Big Bang’ model represents the early 
bursts of genomic disruption. Circles and dots depict cells and mutations respectively. 
Colors correspond to different clones/subclones. Plots on the right represent 2D AF 
distributions of somatic variants in polyps and cancer with dotted lines on 0.5 AF. These 
distributions are characteristic of each mode and can be used for MOE prediction. 
 
CRCs also exhibit large chromosomal aneuploidies with deletion or duplication of 
the entire chromosomes and/or chromosomal arms, which can be characterized in a 
MOE-specific manner. Aneuploidies are expected to be noticeable beginning in adenoma 
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for eruptive MOEs, in which most of the copy number alterations happen early in the 
lineage and the cancer grows out of a clone present in the polyp stage. In an independent 
evolution of polyp and CRC, as in parallel MOE, aneuploidies should only be observed in 
cancer. Similarly, in the stepwise evolution, deleterious early copy number alterations 
would be selected out, leaving only the chromosomally stable clone in polyp stage to 
grow into cancer, at which the growth could tolerate larger scale chromosomal changes. 
The neutral MOE’s copy number alterations status can be more difficult to interpret 
because the lack of selection could imply a possibility of smaller copy number alterations 
but never a larger, more damaging copy number alteration that only cells with selective 
advantage could tolerate. 
Here, it is crucial to note that aneuploidies would not affect the shape of the 
distribution in the 2D plot for several reasons. First, large regions of the genome are 
chromosomally stable in most of the polyp cases. In fact, only three out of the 13 CAP 
cases have greater than 10% of its genome affected by aneuploidies. Another reason is 
that even if the adenoma is affected by aneuploidies, they are mostly subclonal and will 
not shift the AF of the private mutations significantly. This, along with the simultaneous 
shift in AF between the shared and the private SNVs mentioned above, support the notion 
that aneuploidies are unlikely to affect our interpretation of the 2D plot in classifying 
cases by MOEs. All of these reasons also apply to genome doubling. Genome doubling, 
which is found to be commonly associated with increased rate of evolutionary growth in 
colorectal cancer, occurs early in the development and can either affect both adenoma 
and cancer to raise the AF distributions in both axes or, again, affect the entire tissue so 
that the AF in both the private and shared mutations shift together. Therefore, using the 
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relative position of the AF in private mutations with respect to the shared mutations 
serves as a strong criterion in determining the MOE of a case. 
Comparative example of stepwise and eruptive MOEs 
Let’s consider two cases of neoplastic transformation to CRC in our cohort: in 
case A03, where we classified MOE as stepwise, and in case A09, where we classified 
MOE as eruptive (Fig. 3). In each patient, two stages of adenoma (tubular and villous) 
were observed, harvested, and sequenced. In these cases, the tubular and villous polyp 
along with the corresponding resultant cancer were in direct contiguity and present on the 
same histology slide, which likely represents the tissue compartments involved in the 
malignancy that patient A03 developed. Tubular adenoma in A03 had 5,611 somatic 
SNVs with no aneuploidies. Tubular adenoma in A09 had 8,786 somatic SNVs with 
apparent aneuploidies. As expected from the classical Fearon and Vogelstein model, both 
the tubular and villous polyps in A03 had a stop mutation in APC, which is a gene 
recognized to be mutated in many CRC and considered to be involved in initiating 
neoplastic transformation in the colon. Each of the patients also had mutations in one of 
two well-known cancer-driver genes: in KRAS and TP53 in the patient case A03 and in 
TP53 in the patient case A09. The introduction of the TP53 also correlated with 
observation of large amounts of aneuploidies (Fig. 3B,D). In both patient cases, evolution 
to villous adenoma did not change the copy number profile though the copy number 
alterations became more pronounced, likely as a result of better sample purity in the 
villous compared to the corresponding tubular polyp compartment. This is particularly 
noticeable in case A03, in which more somatic SNVs are detected in the villous polyp 
than in its corresponding tubular adenoma, 14,393 vs. 5,611. Consistently, AF of early 
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mutations originated in tubular, including stop mutations in APC and KRAS, are 
increasing and are centered close to 50%, suggesting that one clone dominates this stage. 
In A09, count of SNVs increase only slightly, 8,893 vs. 8,786, with AF of early 
mutations, including stop mutations in APC and TP53, unchanged. As an average AF of 
early mutations is significantly below 50%, mutation-containing cells likely constitute 
only a small fraction of all cells in the villous polyp. 
The copy number profile in the cancer from patient A09 is the same as, but much 
more pronounced, in the villous tissues, suggesting higher purity of cancer cells in the 
cancer compartment than in the villous tissues. In agreement with this, more somatic 
SNVs are detected in cancer compared to the villous polyp, 11,357 vs. 8,893, and the AF 
of early mutations in the adenoma are centered close to 50%, suggesting high purity level 
in this sample. Deletion of the other (not mutated) copy of TP53 gene in the villous 
compartment leads to an even higher AF of a stop mutation in this gene. New mutations 
only found in cancer have much lower AF, indicating that these mutations represent 
subclones in the cancer. Large aneuploidies becoming progressively more definitive since 
their introduction early in the lineage is consistent with eruptive progression. 
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Figure 3: Example of a stepwise (A03) and an eruptive MOE (A09) revealed by somatic mutations analysis 
A&C) Schematic representation of models for origin, presence, and propagation of clonal and subclonal mutations at each stage of 
transformation. Mutations in APC, KRAS, and TP53 are labeled at the corresponding stages of the evolution. The bars on the left 
represent sample purity from SNV AF and CNA analyses. A) Distributions on the right represent the mutations shared by tubular and 
villous low adenomas, and cancer in gray, those shared between tubular and villous low adenomas in yellow, those shared between the 
villous low and cancer in purple, and those that are cancer-specific in blue. C) Distributions on the right represent the mutations shared 
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by tubular and villous low adenomas, and cancer in gray, green, navy blue, and brown colors. Those shared between the villous low 
and cancer are represented in purple and cancer-specific in blue. The distribution on the right has these four colors represented in gray 
for simplicity. B&D) Genome copy number profiles at each stage. In case A03, large aneuploidies are observed only in the cancer 
stage. In case A09, large aneuploidies are observed in the tubular stage and are maintained until the cancer stage. E&G) Distributions 
of AF for somatic SNVs are consistent with stepwise MOE in the case A03 and eruptive MOE in the case A09 (Fig. 2). F&H) 3D 
representation of the AF distributions of SNVs for each case. The height of the distributions, which shows the number of mutations, 
can be used in the comparison of the shared SNVs and private SNVs during the MOE classification.
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Contrary to this, aneuploidies and CNAs in A03 are present only in cancer, in 
which a stop mutation is observed in TP53. However, number of detectable somatic 
SNVs decreases as compared to villous, 8,831 vs. 14,393, with AF of mutation observed 
in adenoma also decreasing. This is most likely due to lower purity in the cancer 
component. New mutations found only in cancer are centered at a similar AF despite 
being subclonal, suggesting a significant selective advantage. All these observations are 
consistent with the gradual accumulation of mutations followed by a selective pressure 
that progressively alters the genomic landscape mostly with SNVs until the late stage of 
cancer, at which point there are large aneuploidies and CNAs. 
Rules and for classifying MOEs 
We defined a set of rules suggesting MOE based on each characteristic signature 
that can be observed in spatial-temporal pattern of SNVs (Table 1). Five rules were 
defined to describe characteristics of each MOE. These rules are related to the number of 
SNVs, the shape of the SNV AF distribution in adenoma and cancer, and the progression 
of CNAs. These rules were based on the theoretical expectations for the four considered 
MOEs (Fig. 2). 
Rule #1 is comparing the number of adenoma- and cancer-specific somatic SNVs 
with the number of somatic SNVs shared between them. Rule #2 is testing whether a gap 
exists in the AF distribution of somatic SNVs in a 2D plot of adenoma vs. cancer (Fig. 2). 
Since selection pressure within a lineage would shift the private SNV AFs further away 
from the shared SNV AFs, a larger gap would signify mutational architecture in later 
stages that is far different from its shared, early clonal mutations. Rule #3 compares the 
spatial distribution of the shared SNV AFs with respect to the private SNV AFs. In 
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evolutionary scenarios with selective pressure, almost all of the later cell population 
would derive from a cell that acquired driver mutations early in the lineage. The high 
prevalence of this cell leads to a private SNV AF that nearly matches the SNV AF of the 
shared, clonal SNV AF. Rule #4 examines whether the early shared SNVs and the later 
shared SNVs are distinguishable based on AF distribution. Although similar to rule #2, 
rule #4 requires both adenoma- and cancer-specific mutations, which will filter out 
neutral evolution in which the lack of selection pressure leads all the mutations in the 
adenoma to be carried forward to the cancer. Similarly, rule #4 filters out eruptive 
evolution given that in eruptive evolution the majority of the mutations found in the 
cancer similar to those in the adenoma due to the late steady state in which mutations 
infrequently accumulate in the CRC beyond those that rapidly accumulated in the early 
precancerous polyp phase and persisted into the cancer. Lastly, rule #5 compares the 
earliest time point at which large aneuploidies are noticeable. 
We then applied majority vote from all rules to classify MOE for each analyzed 
CRC case (Table 2). We found that approximately 70% of CRCs in our dataset evolved 
in a stepwise or a parallel MOE. One case demonstrated an eruptive MOE and three cases 
neutral MOE. Cases A11 and A13 both had a gap in the SNV AF distribution in the 
adenoma but not in the cancer, which corresponded to none of the characteristics of 
MOEs outlined earlier. For A13, the majority of the rules did not apply because of the 
lack of distinction between the private and the shared SNV AF distribution in addition to 
the unusual characteristics in the SNV AF gap between the adenoma and its related 
cancer. One explanation for the unusual gap in the 2D plot is a low purity level in the 
cancer compared to the adenoma, which is supported by the overall low AF distribution 
	25	
in cancer near 0.25. However, if that were indeed the case, it would still not explain the 
fact that the private mutations in cancer appear to have a higher AF than the shared 
SNVs. In fact, pathology review indicates that the macrodissected portion of the cancer 
had 60% tumor density (App. Table 1). For these reasons, cancer-specific mutations 
shifting relative to the mutations shared between both adenoma and cancer can be 
attributed to another possible explanation that the CRC and the physically adjacent CAP 
for cases A11 and A13 arose from different clones independently rather than the CRC 
growing from the same clone as the CAP. Lastly, there is also a possibility that these 
cases represent variations of the four MOEs our rule sets fail to capture or that these cases 
may represent an additional MOE such as an extremely rare polyclonal [43]. 
Table	1:	Rules	to	classify	MOE	for	each	case	of	neoplastic	transformation	
Rules	\	MOE	 Stepwise	 Parallel	 Neutral	 Eruptive	
#1: Count of 
private SNVs 
relative to 
shared SNVs 
Large fraction of 
private in cancer 
and in polyp as 
well as shared 
Majority is 
private in cancer 
and in polyp 
Majority is 
shared 
Majority is 
private in polyp 
and shared 
#2: Gap in the 
SNV AF 
distribution in 
adenoma and in 
cancer 
Yes/Yes Yes/Yes No/No No/Yes 
#3: Position of 
private SNV 
clusters relative 
to the shared 
SNV cluster 
Adenoma-
specific SNV 
AF is lower than 
the shared SNV 
AF 
Both adenoma 
and cancer-
specific SNV 
AFs are equal to 
the shared SNV 
AF 
No private 
mutations 
Both adenoma- 
and cancer-
specific SNV 
AFs are lower 
than the shared 
SNV AF 
#4: In-
distinguishable 
early shared 
from later shared 
SNVs 
No No Yes Yes 
#5: Numerous 
Aneuploidies 
start in 
Cancer (Late) Cancer (Late) N/A Adenoma (Early) 
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Table 2: Rule-based classification of each neoplastic transformation case 
The label s stands for stepwise, p stands for parallel, n stands for neutral, e stands for 
eruptive, and s,p for a combination of stepwise and parallel. For each rule, the samples 
were given the most likely MOE assignments. Then, each sample was assigned the final 
MOE with the majority count across the five rules. 
Cases\Rules	 Rule	1	 Rule	2	 Rule	3	 Rule	4	 Rule	5	 Conclusion	
A02	 s	 s,p	 p	 s,p	 s,p,n	 s,p	
A03	 s	 s,p	 s	 s,p	 s,p,n	 s	
A04	 n	 n	 n	 n,e	 n,e	 n	
A07	 s	 s,p	 p	 s,p	 s,p,n	 s,p	
A08	 p	 s,p	 p	 s,p	 s,p,n	 p	
A09	 e	 e	 s,e	 n,e	 n,e	 e	
A10	 n	 n	 n	 n,e	 -	 n	
A11	 s	 -	 s	 s,p	 n,e	 s	
A12	 s	 s,p	 p	 s,p	 -	 s,p	
A13	 p	 -	 -	 -	 n,e	or	s,p,n	 most	likely	p	
A14	 n	 n	 n	 n,e	 -	 n	
A15	 e	 s,p	 p	 s,p	 -	 p	
A16	 s	 s,p	 s	 s,p	 -	 s	
 
Thus, we only applied the rules #1 and #5 that were pertinent to the case A13 and 
this limitation led to a classification that is less reliable than other cases but the relevant 
rule-based characteristics strongly suggested parallel MOE. It should be noted here that 
due to the nature of synchronous residual polyp of origin, all patient cases exhibit the 
property of branching evolution to some extent, even though it is assumed that the cancer 
sample developed from the adenoma. This is the reason we labeled a few cases to have an 
MOE of s,p as we could not conclusively classify these cases as having stepwise vs. 
parallel MOE. Also, the striking feature of neutral MOE is its lack of selective pressure in 
its lineage, which allows aneuploidies to begin at any point in time. All samples with 
observable aneuploidies were given the additional neutral MOE assignment for rule #5 
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because of this inability to predict the initiation of aneuploidies. Lastly, samples without 
significant aneuploidies were not considered for rule #5. 
Mutational signatures and MOEs 
Next, we broke down the somatic mutations into 96 tri-nucleotide motifs for each 
sample, as Alexandrov previously did in cancer in order to decipher mutational signatures 
[33]. Then, we performed a pairwise comparison, and ordered them by hierarchical 
clustering in order to identify any mutational patterns specific to different MOEs (Fig. 4). 
C>T transitions and C>A transversions seem to contribute the most in distinguishing the 
clusters apart. Additionally, the similarity in the mutational patterns of cancer and their 
matched adenoma samples imply that the mechanism resulting in the shaping of the 
mutational spectra is determined even before adenoma and remains relatively stable in 
the corresponding cancer. 
Clustering of the CAP and cancer samples based on their somatic mutational 
spectra clearly show three major groups of the samples with the same subtypes: case A16 
being in one, cases A10 and A12 being in another, and the rest being in another group. In 
other words, the subtyping of microsatellite-high (MSI-H) or chromosomal instability 
(CIN) case contributes more significantly to the substitution mutation patterns than the 
MOE assignment does. Nevertheless, the same subtype does not guarantee the same 
MOE assignment and this is consistent with two microsatellite-high (MSI-H) cases of 
A10 and A12 having a different MOE. Although the same underlying genetic 
hypermutability results in the two cases having a similar number of mutations, A10 
cancer had a neutral MOE while A12 cancer underwent a stepwise or parallel MOE. The 
genetic hypermutability in both A10 and A12 cases were confirmed in their mutational 
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patterns that are similar to signature 6. According to Alexandrov, signature 6 is 
commonly observed in CRC and is presumed to be associated with compromised DNA 
mismatch repair (App. Fig. 12&13). 
Additionally, the cluster analysis illustrates that the MOE classification is not 
solely dependent on the number of mutations or the MSI status. Despite the A16 cancer 
sample having approximately 10K somatic mutations, it is classified as stepwise MOE as 
most of the other cases. Case A16, due to its unusually high mutational burden that is 
approximately 62 times the amount of somatic mutations found in CIN cases and 6.7 
times the amount found in MSI-H cases, was presumed to have mutations in POLE. This 
was confirmed when the adenoma and cancer mutational spectra were compared to 
signature 10 in the COSMIC database (App. Fig. 14). Since signature 10 is commonly 
observed in CRC and is speculated to be associated with variants in DNA polymerase 
epsilon, this suggested a defective POLE gene [33]. A missense somatic mutation call in 
POLE gene with an AF of 0.25 in the cancer sample of the case A16 accounted for only a 
part of the story since the mutational spectra tell us that the mutations in POLE gene 
happened early in the evolution for such patterns to form both in adenoma and in cancer. 
Indeed, we found two missense mutations in the matched normal sample of the case A16. 
While these could be either germline mutations present throughout or somatic mutations 
that occurred early in development, these mutations could possibly explain the ultrahigh-
mutation rate observed in both the polyp and cancer. The first missense mutation is a 
known SNP on chromosome 12 at position 133220526 that is predicted to have a 
deleterious effect with a SIFT score of 0.03, which is contrary to a benign effect 
predicted by the PolyPhen2 score of 0.104 (SNP ID rs5744934). The second missense 
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mutation, which we believe to be responsible for ultrahigh -mutation effect, is a variant 
that has not been previously reported and is located on chromosome 12 at position 
133220556. Both SIFT and PolyPhen2 predict the resultant amino acid change from 
arginine to proline to have a damaging effect with scores of 0.01 and 0.997, respectively. 
These results imply that defects in specific pathways occurring early in the lineage might 
contribute more to the shaping of these mutational spectra than the particular MOE that 
led to the tumor, though the relationship or cause versus effect of the ultrahigh mutation 
rate and the MOE requires further study in a larger sample set. 
 
Figure 4: Heatmap of the mutational signature analysis and hierarchical clustering 
of all cases 
Each colored panel represent the 16 possible tri-nucleotide combinations corresponding 
to the respective transversion or transition type. The color intensity indicates the 
proportion of the particular mutational signature for that substitution mutation. Bars on 
the left represent the total number of SNVs for each sample in log scale. Clearly visible 
linear pattern over all the samples with high color intensity suggests mutational 
components that are similar in the majority of cases. The samples are clustered into three 
major clusters with A16 samples being in one, A12 and A10 in another, and the rest in 
one cluster. A few samples, indicated by the asterisk, had too few cancer-specific 
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mutations. For these samples, the somatic mutations included those found in the villous 
low adenoma stage. 
 
Enrichment in pathways 
With the list of genes that are significantly mutated in CFP, CAP, and cancer 
cases, compromised functional pathways important in the shaping of the tumor can be 
identified. Only feature represented were the various regions of repeating sequence across 
both adenomas and cancer. For CFP cases, HTLV-1 infection also had significant number 
of mutated genes in its pathway. Other less significantly affected pathway categories 
include glycoproteins, disulfide bonds, and secretory. 
Aneuploidies and MOE 
To determine if a pattern in the CNAs have specific connections to the MOEs, we 
devised a pairwise similarity metric characterizing a chromosomal region of duplications 
or deletions present in both of the samples. The scoring emphasizes only the similarity in 
the pairs and thus gives a small regional variation the same weight as an entire 
chromosomal aberration as long as they are present in both samples. A chromosome can 
have a score between 0 and 1, and the score is higher if more samples have overlapping 
regions of copy number aberrations for this particular chromosome compared to the other 
chromosomes. Because these are scores per chromosome, calculating the summation of 
these scores represents a similarity score between a pair of samples across their entire 
genome. Samples corresponding to each CFP, CAP, and cancer tissue types were 
separately compared and clustered based on these values (Fig. 5). 
In addition to comparing the CNAs across the samples, this similarity metric also 
allowed per-chromosome analysis to identify chromosomes with more recurrent CNAs 
compared to other chromosomes for each of the CFP, CAP, and cancer tissue type. The 
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table below the three panels indicates the chromosomes with this information. Because 
we often observe higher aneuploidy level in cancer as opposed to adenoma, a comparison 
across tissue types may not be possible. Nevertheless, identification of potential markers 
is an essential step towards understanding the clinical significance of tissue types in 
addition to the MOE classification. Chromosomes 7, 17, 20, and 18 had the most 
recurrent copy number alterations across cancer cases, while chromosomes 1, 16, 17, 18, 
15, 20, and 7 were most recurrent across CAP cases. For CFP cases, chromosomes 21, 
22, 1, 13, and 20 had the most recurrent copy number alterations. 
 
Figure 5: Heatmap of the DNA copy number analysis and hierarchical clustering of 
the cases by the tissue type 
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CNAs of the entire genome in each sample are indicated by either deletions (blue) or 
duplications (red). The alternating grey and black bars at the bottom of each panel 
represent the spanning of the chromosomes for regional reference. Samples are grouped 
together by similarity in pairwise CNA comparison using UPGMA and are labeled with 
the corresponding MOE. The bottom panel is the summary of chromosomes with the 
most recurrent changes. Chromosomes with significantly more recurrent changes in CAP 
are represented by the yellow, and cancer by the olive green color. The stepwise MOEs 
are shown in red, parallel in yellow, the combination of two in orange, neutral in gray, 
and eruptive in blue. 
 
Deletions in the p arm of chromosome 1 are significantly recurrent in CFP and 
CAP compared to other chromosomes with p-values of 8x10-4 and 2.4x10-6, respectively. 
This indicates that it is possibly an adenoma-specific marker that is subclonal so that the 
deletion is outcompeted by another subclone without the deletion at the cancer stage. 
Duplications in chromosome 7 are specifically recurrent in CAP (p=4.2x10-5) and cancer 
(p=4.8x10-7). Deletions in chromosomes 17 and 18 are also significantly recurrent 
compared to other chromosomes in CAP with a p-value of 3.3x10-5 for both and in cancer 
with p-values of 6.7x10-6 and 4.8x10-7 respectively. These chromosomes with repeated 
alterations compared to other chromosomes in CAP and cancer demonstrate that these 
copy number alterations may be indicative of malignancy. Similarly, duplications in 
chromosome 13 (p=1.4x10-6), and deletions in chromosome 21 (p=2.6x10-5) and 22 (p 
=1.6x10-5) may be an indicator that the sample is benign as they are most recurrently 
present only in CFP. It is also possible that these are potential markers that signify 
preventative nature against cancer. For example, the large duplication in chromosome 13 
could have a protective effect against the duplication on chromosome 7 as long as the 
deletion on chromosome 17 is not present. Thus, our findings suggest the possibility for 
these markers to be used for potential early detection of the malignant polyps. 
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Utility of exome sequencing in MOE classification 
To determine if our criteria for MOE classification are also applicable to exome 
sequencing data, the 2D plots for case A03 and A09 were re-created based on AF of the 
somatic SNVs found in coding regions only (App. Fig. 17). All features of the 2D plot 
from the whole genome sequencing data were observable in the new 2D plot. Those cases 
with fewer number of SNVs may lose some features of the AF distribution simply due to 
the lower number of SNVs in the exome compared to the genome, but the criteria appears 
to be robust to exome sequencing overall. Similarly, the differential occurrence of 
aneuploidies may still be observable despite the less definitive amplification and CNAs 
from the exome. Our criteria should be applied to an actual exome sequencing data to 
determine whether the MOE classification can still apply to exome sequencing. 
DISCUSSION 
There have been several studies modeling the dynamic process of neoplastic 
transformation based on the spatial characterization of cancer by multi-region sampling 
as well as temporal progression of cancer by comparing the primary cancer sample to 
metastases [34,44]. Traditionally intra-tumor heterogeneity from multiple spatially 
distinct regions of a cancer at one point in time or possibly in corresponding cancer 
recurrence tissues has been one means to evaluate the clonal history of the tumor and 
create phylogenetic trees that depict cancer evolution [45,46]. However, these studies do 
not take into account information of intermediate clones that do not persist through 
malignant transformation. Even if they do, they are often exclusively based on unrelated 
polyps that have not developed into cancer or cancers in which the presumed polyp of 
origin is no longer present, i.e., without directly evaluating the molecular transformation 
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of normal colon through polyp to cancer in the same person. In addition to the studies on 
spatial characterization of cancer, single cell sequencing studies have contributed in the 
in-depth analyses of the clonal lineage in carcinogenesis with the ability to call somatic 
mutations that are missed due to their low AFs [47,43]. Nevertheless, these approaches 
still fail to address the fundamental limitation in the study design of explaining cancer 
evolution from CRC sample alone. 
In this study, we used the cancer adjacent polyp as a snapshot of the CRC clonal 
lineage to infer the pre-cancer time course. Numerous studies have reported that the 
remnant features of primary tumors in their recurrent metastatic tumors, suggesting that 
the determination of whether the tumor will metastasize could possibly come early during 
the primary tumor progression [44,46,48]. Similarly, we posit that the cancer’s MOE 
arises in polyp compartment, which precedes the presence of cancer. 
We defined a set of criteria that is based on the information from the presence of 
both cancer and its matching polyp in order to classify each case into one of four MOEs. 
Our defined criteria are almost universal as we were able to classify all but two cases into 
a distinct MOE with no ambiguity. Complications in classifying the two cases could stem 
from those cases not belonging to any of the established four MOEs. It is possible that the 
two cases have undergone an extremely rare and not well-understood MOE such as CRC 
with polyclonal origin [43]. For every mode, we found at least one case corresponding to 
it. Approximately 70% of CRCs in our dataset evolved in a stepwise or a parallel fashion, 
although we should note that all cases are expected to exhibit features of parallel 
evolution, given the nature of our experiment i.e. existence of matched polyp and CRC. 
We also found that the non-aggressive cases in which patients with stage II and III CRC 
	35	
survived their cancer exhibited all four stepwise, parallel, neutral, or eruptive MOE. This 
implies that MOE does not determine or at least is not the only determinant of clinical 
aggressiveness. 
Our data on the relationship between the MOE and the somatic substitution 
mutations show that the patterns in the somatic substitutions were more significantly 
influenced by the underlying mutational mechanisms than by their MOEs. It also 
indicates that several different mutational mechanisms can lead to the same MOE and 
two different MOEs can have similar mutational mechanisms. Similarly, CNA patterns 
did not directly correlate with the MOE. This indicates that mutations in specific genes or 
pathways, and sequential order of deletions and duplications could determine the MOE of 
a CRC. While it is possible that factors other than the mutational mechanism – such as 
somatic variants in particular pathways, germline variants, and perhaps the microbiome – 
that can determine the MOE of a CRC, it is also possible that the relationship between 
MOE and mutational mechanism simply could not be found given our small sample size. 
Thus our finding warrants further study in understanding the relationship between the 
two. 
Currently, the MOE assignment requires both the cancer and the matching polyp, 
so the CFPs were not assigned the MOE. Yet, if the MOE could be determined at a polyp 
stage solely based on the transformation from normal colon cell to the polyp, we could 
predict the clinical phenotype of the patient as well as the mutational architecture of any 
later stages. Our analysis of the mutational spectra illustrates that the CFPs cluster among 
the CAPs. Similarly, CFPs and CAPs seemed to share some of the recurrent copy number 
alterations. This comparison between the CFPs and CAPs accounts for the potential bias 
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in the representation of CAPs and leaves open the possibility of assigning the MOEs at 
the polyp stage in order to determine whether it progresses to cancer or not. 
CONCLUSION 
Overall, our study is the first to define specific criteria to link the MOEs to 
mutational characteristics in patient cases using cancer and its residual polyp of origin. 
Just as carcinogenesis models are relevant across different cancers, this MOE 
classification of CRC may apply to other cancer types with premalignant stages including 
PanINs in pancreatic cancer and ductal hyperplasia that precedes breast cancer [49,50]. 
Use of MOE in the study of neoplastic transformation promises to provide additional 
insight into the genomic landscape of cancer as our classification signifies a 
characterization of cancer that is vastly different from the conventional genomic profiling 
using somatic SNVs and CNAs. Combining single cell analysis and intra-tumoral/intra-
polyp heterogeneity approaches focusing on the more precise tracking of cancer 
evolution from the early, perhaps polyp-specific event initiating neoplastic transformation 
will most likely provide additional insights into the details of malignant transformation in 
CRC. This insight, along with the relevance of CRC MOE modeling in other cancer 
types, may better our understanding of carcinogenesis in order to improve 
prognostication and to develop treatments targeted at the most relevant molecular events 
that drive both malignant transformation and ultimately progression.  
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APPENDIX A: Clinical, pathological, and genomic information 
 
Appendix Table 1: Clinical, pathological, and genomic information for all CRC 
RPO+ cases 
Microsatellite instable label with high or low level vs. chromosomal instability; modes of 
evolution; level of cancer purity; aneuploidy level; APC mutation percentage in cancer; 
TP53 mutation percentage in cancer; KRAS mutation percentage in cancer; clinical 
aggressiveness; and tumor staging. 
Cases	 MSI/	CIN	 MOE	
Purity	
(%)	
Aneuploidy	Level	
(%)	 APC	 TP53	 KRAS	 Aggressiveness	 Stage	
A02	 CIN	 s,p	 90	 34.44	 0	 56.7	 0	 Aggressive	 4	
A03	 CIN	 s	 80	 25.81	 37.9	 21.9	 46.7	 Aggressive	 4	
A07	 CIN	 s,p	 70	 27.61	 51.9	 40.9	 31	 Aggressive	 2	
A08	 CIN	 p	 50	 31.28	 20	 44.8	 25	 Non-aggressive	 3	
A09	 CIN	 e	 80	 27.19	 32	 69.6	 0	 Non-aggressive	 1	
A10	 MSI-H	 n	 70	 3.75	 0	 0	 0	 Non-aggressive	 1	
A11	 CIN	 s	 40	 22.08	 0	 16.7;	15.2	 0	 Non-aggressive	 2	
A12	 MSI-H	 s,p	 70	 2.63	 23.3	 25	 0	 Non-aggressive	 2	
A13	 CIN	 p	 60	 8.76	 0	 2.8	 0	 Non-aggressive	 2	
A14	 CIN	 n	 90	 3.75	 35.7	 0	 32.1	 Non-aggressive	 3	
A15	 CIN	 p	 50	 9.15	 20.7	 0	 26.7	 Non-aggressive	 3	
A16	 MSI-H	 s	 60	 4.41	 0	 0	 0	 Non-aggressive	 2	
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APPENDIX B: Analysis summary for the rest of the cases 
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B 
Appendix Figure 1: Analysis summary for case A02, which is either a stepwise or 
parallel lineage 
A) Copy number profile across all chromosomes. Large aneuploidies are observed only at 
the cancer stage. B) 2D allele frequency distribution is in agreement with the parallel 
scenario, but stepwise scenario is also possible (see Fig. 2). 3D representation of the AF 
distributions of SNVs is shown on the bottom right. The height of the distributions, which 
shows the number of mutations, indicates large fraction of both the shared SNVs and 
private SNVs. 
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Appendix Figure 2: Analysis summary for case A04, which is likely a neutral lineage 
A) Copy number profile across all chromosomes. Large aneuploidies are observed before 
the cancer stage. B) 2D AF distribution is in agreement with the neutral lineage (see Fig. 
2). 3D representation of the AF distributions of SNVs is shown on the bottom right. The 
height of the distributions, which shows the number of mutations, indicates that majority 
is shared SNVs. 
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Appendix Figure 3: Analysis summary for case A07, which is either a stepwise or 
parallel lineage 
A) Copy number profile across all chromosomes. The entire chromosome 7 is duplicated 
early in the progression, but large aneuploidies are not observed until later in the cancer 
stage. B) 2D allele frequency distribution is in agreement with the parallel scenario, but 
stepwise scenario is also possible (see Fig. 2). 3D representation of the AF distributions 
of SNVs is shown on the bottom right. The height of the distributions, which shows the 
number of mutations, indicates large fraction of both the shared SNVs and private SNVs. 
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Appendix Figure 4: Analysis summary for case A08, which is likely a parallel 
lineage 
A) Copy number profile across all chromosomes. The deletion on chromosome 4 
progressively becomes larger until the cancer stage, at which it is no longer observed; it 
appears to be subclonal. Large aneuploidies are observed only at the cancer stage. B) 2D 
AF distribution is in agreement with the parallel lineage (see Fig. 2). 3D representation of 
the AF distributions of SNVs is shown on the bottom right. The height of the 
distributions, which shows the number of mutations, indicates that majority is private 
SNVs. 
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Appendix Figure 5: Analysis summary for case A10, which is likely a neutral lineage 
A) Copy number profile across all chromosomes. No large aneuploidies are observed. B) 
2D allele frequency distribution is in agreement with the neutral lineage (see Fig. 2). 3D 
representation of the AF distributions of SNVs is shown on the bottom right. The height 
of the distributions, which shows the number of mutations, indicates that majority is 
shared SNVs. 
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Appendix Figure 6: Analysis summary for case A11, which is likely a stepwise 
lineage 
A) Copy number profile across all chromosomes. Large aneuploidies are observed before 
the cancer stage. B) 2D allele frequency distribution is in agreement with the stepwise 
lineage (see Fig. 2). 3D representation of the AF distributions of SNVs is shown on the 
bottom right. The height of the distributions, which shows the number of mutations, 
indicates large fraction of both the shared SNVs and private SNVs. 
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Appendix Figure 7: Analysis summary for case A12, which is either a stepwise or 
parallel lineage 
A) Copy number profile across all chromosomes. No large aneuploidies are observed. B) 
2D allele frequency distribution is in agreement with the stepwise scenario, but stepwise 
scenario is also possible (see Fig. 2). 3D representation of the AF distributions of SNVs 
is shown on the bottom right. The height of the distributions, which shows the number of 
mutations, indicates large fraction of both the shared SNVs and private SNVs. 
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Appendix Figure 8: Analysis summary for case A13, which is likely a parallel 
lineage 
A) Copy number profile across all chromosomes. Large aneuploidies are observed only at 
the cancer stage. B) 2D allele frequency distribution does not follow any of the scenarios, 
but based on the number of mutations, it is likely to be a parallel lineage (see Fig. 2). 3D 
representation of the AF distributions of SNVs is shown on the bottom right. The height 
of the distributions, which shows the number of mutations, indicates that majority is 
private SNVs. 
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Appendix Figure 9: Analysis summary for case A14, which is likely a neutral lineage 
A) Copy number profile across all chromosomes. No large aneuploidies are observed. B) 
2D AF distribution is in agreement with the neutral scenario (see Fig. 2). 3D 
representation of the AF distributions of SNVs is shown on the bottom right. The height 
of the distributions, which shows the number of mutations, indicates that majority is 
shared SNVs. 
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Appendix Figure 10: Analysis summary for case A15, which is likely a parallel 
lineage 
A) Copy number profile across all chromosomes. No large aneuploidies are observed. B) 
2D AF distribution is in agreement with the parallel lineage (see Fig. 2). 3D 
representation of the AF distributions of SNVs is shown on the bottom right. The height 
of the distributions, which shows the number of mutations, indicates large fraction of 
polyp-specific SNVs and shared SNVs. 
  
Normal	
	
	
		
Near	Normal	
	
	
		
Tubular	Low	
	
	
	
	
Villous	Low	
	
		 	
Cancer	
Co
ve
ra
ge
	(R
ea
ds
)	
	55	
A 
B 
 
Appendix Figure 11: Analysis summary for case A16, which is likely a stepwise 
lineage 
A) Copy number profile across all chromosomes. No large aneuploidies are observed. B) 
2D AF distribution is in agreement with the stepwise lineage (see Fig. 2). 3D 
representation of the AF distributions of SNVs is shown on the bottom right. The height 
of the distributions, which shows the number of mutations, indicates large fraction of 
both the shared SNVs and private SNVs. 
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APPENDIX C: Mutational signature analysis of A10, A12, and A16 
 
 
 
 
 
 
Appendix Figure 12: Mutational spectra of the villous low and cancer in the case 
A10 
The mutational spectra of the case A10 are compared to the mutation signature 6 from the 
COSMIC database [33]. The significant contributions from C>T and C>A substitutions 
clearly the resemble the case A10. Signature 6 is presumed to be associated with 
defective DNA mismatch repair found in MSI tumors (see 
http://cancer.sanger.ac.uk/cosmic/signatures). 
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Appendix Figure 13: Mutational spectra of the villous low and cancer in the case 
A12 
The mutational spectra of the case A12 are compared to the mutation signature 6 from the 
COSMIC database [33]. The significant contributions from C>T and C>A substitutions 
clearly the resemble the case A12. Signature 6 is presumed to be associated with 
defective DNA mismatch repair found in MSI tumors (see 
http://cancer.sanger.ac.uk/cosmic/signatures). 
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Appendix Figure 14: Mutational spectra of the villous low and cancer in the case 
A16 
The mutational spectra of the case A16 are compared to the mutation signature 10 from 
the COSMIC database [33]. The significant contributions from C>T and C>A 
substitutions clearly the resemble the case A16. Signature 10 is presumed to be associated 
with mutations in POLE gene (see http://cancer.sanger.ac.uk/cosmic/signatures). 
	59	
 
 
 
 
 
 
 
 
Appendix Figure 15: Mutational spectra of the villous low and cancer in the CIN 
cases 
The mutational spectra of the CIN cases are compared to the mutation signature 1 and 5 
from the COSMIC database [33]. The significant contributions from C>A and C>T 
	60	
substitutions clearly the resemble the CIN cases. Signature 1 is presumed to be associated 
with sporadic deamination of 5-methylcytosine but signature 5 is not yet known to be 
associated with particular mechanisms (see http://cancer.sanger.ac.uk/cosmic/signatures).  
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APPENDIX D: Significantly recurrent CNA by chromosomes for each tissue types 
 
Appendix Figure 16: Histogram of the similarity in the CNA per chromosomes for 
cancer, CAP, and CFP 
For cancer samples, copy number changes in the chromosomes 18, 20,17, and 7 were 
significantly more recurrent compared to the other chromosomes. For CAPs, copy 
number changes in the chromosomes 7, 20,15, 18, 17, 16, and 1 were significantly 
recurrent compared to the other chromosomes. For CFPs, copy number changes in the 
chromosomes 20, 13, 1, 22, and 21 were significantly recurrent compared to the other 
chromosomes. 
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APPENDIX E: Utility of exome sequencing in MOE classification A
	B
	
Appendix Figure 17: Allele frequency distributions of SNVs in the coding regions 
only 
A) 2D and 3D AF distributions of SNVs in coding regions for case A03. General shape 
and the two gaps representing the stepwise evolution remain observable. B) 2D and 3D 
AF distributions of SNVs in coding regions for case A09. General shape and the single 
gap in cancer representing the eruptive evolution remain observable. 
